SCHEMBL20564907

SCHEMBL20564907

COc1ccc(COc2nc(-n3ccnc3)nc(Cl)c2C(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TBXAS1 P24557 3/20 0.40
PDE5A O76074 2/20 0.40
PDE3B Q13370 2/20 0.40
PDE3A Q14432 2/20 0.40
IDO1 P14902 1/20 0.40
NOS2 P35228 3/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 1/20 0.39
CYP19A1 P11511 5/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20564651 0.84 CYP26A1 (0.47) KDM4EALDH1A1TBXAS1PDE5APDE3B
SCHEMBL20564189 0.83 CYP26A1 (0.49) KDM4EALDH1A1KMT2ATBXAS1PDE5A
SCHEMBL20564805 0.79 CYP3A4 (0.37) KDM4EALDH1A1KMT2ATDP1TBXAS1
SCHEMBL20565461 0.79 KDM5B (0.38) KDM4EALDH1A1KMT2ATDP1TBXAS1
SCHEMBL20564303 0.79 MAOB (0.43) ALDH1A1IDO1CNR1CNR2
SCHEMBL501385 0.78 MAOB (0.42) ALDH1A1IDO1CNR1CNR2
SCHEMBL20564820 0.77 CYP19A1 (0.38) KDM4EALDH1A1KMT2ATDP1TBXAS1
SCHEMBL20564744 0.77 SMN1; SMN2 (0.38) ALDH1A1KMT2ACNR1CNR2
SCHEMBL20564425 0.75 LMNA (0.52) ALDH1A1KMT2ACNR1CNR2
SCHEMBL20958063 0.75 TSHR (0.42) ALDH1A1KMT2ATDP1TBXAS1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
WO-2018213777-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE KDM5A, KDM5B, KDM5C KDM4E 13/4885ALDH1A1 1687/4885KMT2A 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.